Hosted on MSN7h
William Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform RecommendationFintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a ...
William Blair analyst Andy Hsieh last night initiated coverage of Mersana Therapeutics (MRSN) with an Outperform rating. The firm believes ...
Mersana Therapeutics, Inc. CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and ...
William Blair initiated coverage on Mersana Therapeutics, Inc. (NASDAQ:MRSN) with an Outperform rating. The firm's analyst cited the company's potential in the antibody-drug conjugates (ADCs) market ...
Mersana Therapeutics, Inc. (MRSN) stock price is 0.61 and Mersana Therapeutics, Inc. (MRSN) 10-day simple moving average is 0.59. Mersana Therapeutics, Inc. (MRSN) stock price is 0.61 and Mersana ...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zoetis (ZTS – Research Report), Terns ...
Pre-Market: 5:08:48 a.m. EST Loading Chart for MRSN ...
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...
After hours: 7:57:32 p.m. EST Loading Chart for CGTX ...
Sanofi S.A. Part Cert 0.02% €8.03M ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback